Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 11, 2023
Asensus Surgical, Inc. (NYSE American: ASXC) has announced the release date for its 2023 first quarter financial and operational results, set for May 11, 2023, after market close. The company will conduct a conference call later that day at 4:30 p.m. ET to discuss these results, which can be accessed via telephone or through a live audio webcast. Asensus is focused on transforming surgery with its Performance-Guided Surgery™ approach, leveraging technologies including the Senhance Surgical System and the upcoming LUNA™ Surgical System. These innovations aim to enhance surgical outcomes by integrating machine vision and deep learning into the surgical process.
- Scheduled release for Q1 2023 financial results may boost investor confidence.
- Performance-Guided Surgery technology addresses current surgical outcomes and economic shortcomings.
- Senhance Surgical System is available for sale in multiple countries, increasing market reach.
- None.
RESEARCH TRIANGLE PARK, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ (PGS), announced today that it plans to release 2023 first quarter financial and operating results after the market closes on Thursday, May 11, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial 1-844-826-3033 for domestic callers and 1-412-317-5185 for international callers, approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
invest@asensus.com
443-213-0499
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
FAQ
When will Asensus Surgical release its Q1 2023 financial results?
What time is the Asensus Surgical conference call scheduled?
How can I access the Asensus Surgical financial results conference call?
What is the focus of Asensus Surgical's business?
What systems does Asensus Surgical offer?
